Elsevier

Maturitas

Volume 21, Issue 2, February 1995, Pages 153-157
Maturitas

Sub-clinical worsening of bronchial asthma during estrogen replacement therapy in asthmatic post-menopausal women

https://doi.org/10.1016/0378-5122(94)00890-JGet rights and content

Abstract

Background: Changes in asthma activity, in part related to the female hormonal profile, have been observed during pre-menstrual periods and during pregnancy. Estrogen replacement therapy (ERT) is an accepted routine treatment for post-menopausal women. The effect of ERT on disease activity in post-menopausal asthmatic women has not been investigated in the past and is the subject of the present study. Methods: Fifteen post-menopausal women with mild to moderate asthma completed two 30-day periods in which they measured peak expiratory flow (PEF) at home and filled in a daily diary of asthma-related symptoms. The first monitoring period was pre-ERT and the second was during ERT. In addition spirometry was performed on each woman three times, twice pre-ERT and once during ERT. Results: The average daily PEF decreased from 241 (57.9, S.D.) l/min pre-ERT to 226.7 (62.7) l/min during ERT (P < 0.004). Significant differences between the two study periods were also found in morning and evening PEF values. Diurnal variation, measured as the difference between morning and evening PEF values, decreased significantly from 22.3 (26.7) l/min pre-ERT to 17.5 (26.8) l/min during ERT (P < 0.007). The average daily consumption of bronchodilator inhalers increased significantly from 3.7 puffs/day pre-ERT to 4.3 puffs/day during ERT (P < 0.006). Although the differences in spirometry between the two periods did not reach statistical significance, a trend towards a worsening of the obstructive disorder during ERT was observed. However, the general feeling of well-being of the asthmatics did not change during the two periods. Conclusions: During ERT a sub-clinical worsening of disease activity was found in post-menopausal women with mild to moderate asthma. We also detected a decrease in diurnal variation. Our findings should be substantiated by additional studies.

References (12)

There are more references available in the full text version of this article.

Cited by (51)

  • Estrogen replacement therapy and asthma

    2013, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    The authors also found that the age-adjusted increased relative risk for asthma was positively dose-related (p for trend = 0.007) [72]. This finding is in accordance with the results of an other contemporary study showing a reduction in the measured peak expiratory flow and an increased consumption of bronchodilators by inhalation in 15 postmenopausal women during ERT [80]. The potential detrimental effects of ERT on asthma in menopausal and postmenopausal women has been reported in a series of successive studies.

  • Animal models of airway inflammation and airway smooth muscle remodelling in asthma

    2009, Pulmonary Pharmacology and Therapeutics
    Citation Excerpt :

    In the earliest reports documenting premenstrual asthma, it was hypothesized that a high level of estrogen may play a role in the aetiology of the syndrome [95,98], and it was even once referred to as “endocrine allergy” [99]. Although it is quite possible that female sex hormones are responsible for the observed premenstrual asthma symptoms, clinical studies that correlate asthma with the use of oral contraceptives or hormone replacement therapy show conflicting and inconclusive data on the role of estrogen and progesterone [100–110]. Small rodent models may provide clues toward specific mechanistic pathways that might confound inflammation and remodelling of the airways in asthmatic women.

  • Role of estradiol metabolism in asthma

    2009, Bioscience Hypotheses
    Citation Excerpt :

    Furthermore, obese women, who have increased E2 plasma levels, are at a higher risk for asthma and have elevated atopy [4–6] and “premenstrual asthma” is a well-recognized clinical entity [7,8]. Also, use of estrogens exacerbates the disease in asthmatic postmenopausal women [9] and increases the rate of newly diagnosed asthma [10]. Yet, strong evidence regarding clear beneficial or adverse effects of E2 in asthma is lacking.

View all citing articles on Scopus
View full text